TGTX

TG-1701 (BTK Inhibitor)

B-Cell Malignancies

Phase 1

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: TG-1701 (BTK) in B-Cell Malignancies

  • ClinicalTrial.gov NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA


PRESS RELEASES

MARKET

  • 115,000 Americans living with CLL

  • ~20,000 newly-diagnosed patients each year

  • ~20,000 previously treated patients seeking treatment each year

  • Source - (slide 11) Raymond James 2020 Human Health Innovation Conference 

MECHANISM OF ACTION / RATIONALE


B-cell receptor (BCR) signaling is crucial for normal B-cell development and supports the survival and growth of malignant B-cells in patients with B-cell leukemias or lymphomas. Targeting BTK, an essential element of BCR signaling pathway which regulates the survival, activation, proliferation, and differentiation of B lymphocytes, has shown remarkable efficacy with an acceptable safety profile in B-cell malignancies.

Updated by HC

TGTX, TG-1701, B-Cell_Malignancies

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Will TGTX's Unity CLL PFS Read...

QUESTION: Is TGTX going to report positive results that increases their stock price, when they report their upcoming Phase 3 Unity-CLL PFS readout*? On Sept. 25, 2018, TGTX took a big hit to its cred...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon